The content on this site is intended for healthcare professionals only
Dr Karol presents, at a press conference at ASH 2015, results from a study looking at genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukaemia.
Read the news story and watch Dr Stock's comment on this study or the video interview with Dr Karol for more information.
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Advancements in paediatric Acute lymphoblastic leukemia management
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Multiple myeloma In Rwanda: The need for further research
Addressing the rise of multiple myeloma in Rwanda
A patient-reported questionnaire may eliminate the need for an ophthalmic exam before belantamab mafodotin dosing in TI NDMM
More effective treatment options required for patients with MM post lenalidomide exposure
Lower levels of inflammatory markers and tumour burden is linked to improvements in PFS with Ide-Cel in R/R multiple myeloma
Isatuximab in combination with pomalidomide and dexamethasone shows promising efficacy in 2nd line RRMM
